ZL-1310 + Investigator's Choice of Therapy
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Small-cell Lung Cancer
Conditions
Small-cell Lung Cancer
Trial Timeline
Nov 30, 2025 → Nov 30, 2028
NCT ID
NCT07218146About ZL-1310 + Investigator's Choice of Therapy
ZL-1310 + Investigator's Choice of Therapy is a phase 3 stage product being developed by Zai Lab for Small-cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07218146. Target conditions include Small-cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07218146 | Phase 3 | Recruiting |
Competing Products
20 competing products in Small-cell Lung Cancer